Material and Method: In this retrospective study, 30 patients with Ex-PRESS mini glaucoma implant surgery with Mytomicin C were included. The demographic characteristics, preoperative and postoperative IOP, visual acuity, number of glaucoma medication, peroperative and postoperative complications were formed. The success was considered in the patients with IOP between 6-21 mmHg with/without antiglaucoma therapy after surgery; and the failure was considered in patients with IOP above 21 mmHg and/or the need for a second surgery.

Results: Patients were male and 20 (66.6%), 10 (33.3%) were female with mean age of 62.9±10.7 (40-83). The mean follow-up time was 9.48±7.62 months (range, 6-24 months). The Ex-PRESS implant surgery were performed to 17 patients with primary open angle glaucoma (POAG), and 6 with pseudoexfoliative glaucoma, 3 with pigmentary glaucoma, 4 with neovascular glaucoma. The mean preoperative IOP was 26.6±10.0 mmHg with maximum medical therapy and 18.55±3.78 mmHg at the final control after surgery (p<0.001). Preoperative medication use was 3.24±1.0 and 0.28±1.6 at the final control after surgery (p<0.001). There was no peroperative complication, and postoperative hyphema (2), choroidal detachment/hypotension (2), wound dehiscence (2), corneal decompensation (1) and exposure of the implant (1) were observed. Implants were removed due to corneal decompensation in a patient, implant exposure in a patient and high IOP in two patients with neovascular glaucoma.

Conclusion: Ex-PRESS mini glaucoma implant to provide IOP reduction in glaucoma patients, is a safe and effective surgery. However, according to trabeculectomy it is an expensive method, and we believe that it should not be considered as the first choice. Keywords : Ex-PRESS, glaucoma, implant